Latest Insider Positions


Cohen Fred E is listed as an insider in the following companies: GHDX / Genomic Health, Inc. BCRX / BioCryst Pharmaceuticals, Inc. FPRX / Five Prime Therapeutics, Inc. CDNA / CareDx, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
GHDX / Genomic Health Director 73,390
CDNA / CareDx Director 37,901
BCRX / BioCryst Pharmaceuticals Director 119,410
FPRX / Five Prime Therapeutics Director 24,807

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-07-01 GHDX / Genomic Health A 198 73,390 0.27 50.40 9,979
2018-06-20 CDNA / CareDx A 5,000 37,901 15.20
2018-04-01 GHDX / Genomic Health A 319 73,192 0.44 31.29 9,982
2018-01-01 GHDX / Genomic Health A 292 72,873 0.40 34.20 9,986
2017-10-01 GHDX / Genomic Health A 311 72,581 0.43 32.09 9,980
2017-09-18 BCRX / BioCryst Pharmaceuticals S -54,250 119,410 -31.24 5.42 -294,035 647,202 -45.43
2017-09-18 BCRX / BioCryst Pharmaceuticals M 54,250 173,660 45.43 4.27 231,648
2017-07-13 CDNA / CareDx A 5,000 32,901 17.92
2017-07-01 GHDX / Genomic Health A 307 72,270 0.43 32.55 9,993
2017-06-01 BCRX / BioCryst Pharmaceuticals A 1,941 119,410 1.65 5.15 9,996
2017-05-19 GHDX / Genomic Health S -8,250 71,963 -10.29 29.5448 -243,745 2,126,132 -11.46
2017-05-19 GHDX / Genomic Health M 8,250 80,213 11.46 14.37 118,552
2017-05-18 GHDX / Genomic Health S -16,500 71,963 -18.65 29.8812 -493,040 2,150,341 -22.93
2017-05-18 GHDX / Genomic Health M 8,250 88,463 10.29 17.59 145,118
2017-05-18 GHDX / Genomic Health M 8,250 80,213 11.46 18.50 152,625
2017-05-16 GHDX / Genomic Health S -8,250 71,963 -10.29 30.679 -253,102 2,207,753 -11.46
2017-05-16 GHDX / Genomic Health M 8,250 80,213 11.46 18.13 149,572
2017-04-01 GHDX / Genomic Health A 317 71,963 0.44 31.49 9,982
2017-04-01 CDNA / CareDx A 5,271 27,901 23.29
2017-03-01 BCRX / BioCryst Pharmaceuticals A 1,602 117,469 1.38 6.24 9,996
2017-01-01 GHDX / Genomic Health A 340 71,646 0.48 29.39 9,993
2017-01-01 CDNA / CareDx A 3,391 22,630 17.63
2016-12-01 BCRX / BioCryst Pharmaceuticals A 1,788 115,867 1.57 5.59 9,995
2016-10-01 GHDX / Genomic Health A 345 71,306 0.49 28.92 9,977
2016-10-01 CDNA / CareDx A 2,643 19,239 15.93
2016-09-01 BCRX / BioCryst Pharmaceuticals A 2,433 114,079 2.18 4.11 10,000
2016-07-15 CDNA / CareDx A 5,000 16,596 43.12
2016-07-01 GHDX / Genomic Health A 373 70,961 0.53 26.74 9,974
2016-07-01 CDNA / CareDx A 2,695 11,596 30.28
2016-05-31 BCRX / BioCryst Pharmaceuticals A 2,581 111,646 2.37 3.39 8,750
2016-04-01 CDNA / CareDx A 1,954 8,901 28.13
2016-04-01 GHDX / Genomic Health A 392 70,588 0.56 25.48 9,988
2016-02-29 BCRX / BioCryst Pharmaceuticals A 4,396 109,065 4.20 1.99 8,748
2016-01-11 FPRX / Five Prime Therapeutics M 12,500 24,807 101.57 12.70 158,750
2016-01-11 FPRX / Five Prime Therapeutics M 4,065 12,307 49.32 7.26 29,512
2016-01-11 FPRX / Five Prime Therapeutics M 4,065 8,242 97.32 5.54 22,520
2016-01-11 FPRX / Five Prime Therapeutics M 4,065 4,177 3,629.46 8.49 34,512
2016-01-01 GHDX / Genomic Health A 284 70,196 0.41 35.20 9,997
2016-01-01 CDNA / CareDx A 1,836 6,947 35.92
2015-11-30 BCRX / BioCryst Pharmaceuticals A 824 104,669 0.79 10.61 8,743
2015-10-01 GHDX / Genomic Health A 468 69,912 0.67 21.34 9,987
2015-10-01 CDNA / CareDx A 1,008 5,111 24.57
2015-08-31 BCRX / BioCryst Pharmaceuticals A 751 103,845 0.73 11.64 8,742
2015-07-01 GHDX / Genomic Health A 365 69,444 0.53 27.34 9,979
2015-07-01 CDNA / CareDx A 1,227 4,103 42.66
2015-05-29 BCRX / BioCryst Pharmaceuticals A 780 103,094 0.76 11.21 8,744
2015-04-01 CDNA / CareDx A 1,075 2,876 59.69
2015-04-01 GHDX / Genomic Health A 328 69,079 0.48 30.43 9,981
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of Cohen Fred E include the following: 14159, L.P., 667, L.P., ABERCROMBIE GEORGE B, ADAGE CAPITAL PARTNERS GP, L.L.C., ANHALT HENRY, ATWOOD BRIAN G, Abernethy Amy, Adage Capital Advisors, L.L.C., Adage Capital Partners, L.P., Allen Dick, Anacone Robert, Anderson Bonnie H, Atchinson Robert, BAKER BROS. ADVISORS LP, BAKER FELIX, BAKER JULIAN, BARRETT M JAMES, BARRIS PETER J, BASKETT FOREST, BERGER DAVID B, BERGER FRANKLIN M, BISHOP JOHN L, BLICKENSTAFF KIM D, BONDERMAN DAVID, BYERS BROOK H, Babu Yarlagadda S, Baker Bros. Advisors (GP) LLC, Baker Bros. Investments II, L.P., Baker Bros. Investments, L.P., Baker Brothers Life Sciences LP, Baker Kevin Paul, Baker/Tisch Investments, LP, Barnes Alane P, Bell Michael Brian, Belsky Marc, Bickerstaff George, Boesgaard Lars, Borges Luis, Brooks Julie, CAHILL EDWARD L, COULTER JAMES G, Cajigas John, Cole G Bradley, Collins Helen Louise, Constanti Charles, DeFonzo Joshua, Dhingra Kapil, Douglas R Lee, Doyle Michael P., EASTHAM KARIN, EPSTEIN ROBERT S, Erck Stanley C, FUCHS HENRY J, Febbo Phillip G., GAGNON NEIL, GORDON KEVIN K, GRAHAM GINGER L, GREENE HOWARD E JR, Goldberg Michael, Gross Phillip, Gujrathi Sheila, Guyer Shelly D, HAGSTROM WILLIAM A, HANSEN BRIAN B, Hall Christopher M, Hambleton Julie, Hutson Nancy J, INGRAM ROBERT ALEXANDER, ISALY SAMUEL D, Irving Bryan, JONES EVAN/ FA, Jensen Peder, KERINS PATRICK J, KLEINER PERKINS CAUFIELD & BYERS XII, LLC, KOLLURI KRISHNA KITTU, KPCB XII Associates, LLC, KPCB XII Founders Fund, LLC, Karlsson Anders, Kennedy Keith, King Sasha, Knickerbocker Aron Marc, LEE KENNETH B JR, LIVINGSTON RANDALL S, LUDLUM KEN, Leber Laura, MCDADE MARK, MCGIRR DAVID W J, MILLER DOUGLAS S, MOTT DAVID M, Maag Peter, Mary Beth Duseau, McCardell AmyJo, McEachron Kim, Meyer Matthew J., Midroc Invest AB, Morrison Susan, NEA 13 GP, Ltd, NEA Partners 13, Limited Partnership, NEW ENTERPRISE ASSOCIATES 13 LP, Narajowski Walter M., Nelles Mitchell J, Nicholson Garry A, Nova Tina Susan, ORBIMED ADVISORS LLC, OrbiMed Capital GP III LLC, Parker Geoffrey M., Patel Sanj K, Pla Frederic, Popovits Kimberly J, Powell Duncan Thomas, Powell Lynne, RINGO WILLIAM R, ROEDER DOUGLAS A, Radford Jason W., Rubinstein Linda M, SANDELL SCOTT D, SANDERS CHARLES A, SILVERSTEIN JONATHAN, SMITH LONNIE M, SNYDERMAN RALPH, SOBIESKI STEVEN, STAAB THOMAS R II, Sarena Francis Willard, Shak Steven, Sheridan John F, Sheridan William P, Sikorski Robert Steven, Sninsky John Joseph, Stonehouse Jon P, THOMAS PAUL, TPG Group Holdings (SBS) Advisors, Inc., TREU JESSE I, TWOMEY CHRISTOPHER J, VALERIANI NICHOLAS J, Valencia Richard P., Vaughn James J, Viswanathan Ravi, Vosseller Leigh, Weller Harry R, Whitson Todd, Williams Lewis T, Yee James P, . Peers are determined by cross-linking the filings of Cohen Fred E with insider filings of others at the same companies.

Related News Stories

QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe

2018-07-13 zacks
On Jul 12, we issued an updated research report on QIAGEN N.V. (QGEN - Free Report) . The company's business is expected to get a boost from its flourishing molecular diagnostic market, international expansion, extended test menu and growth-driving strategic collaborations. (4-0)

Here's Why You Should Add Edwards Lifesciences (EW) Now

2018-07-13 zacks
Edwards Lifesciences Corporation (EW - Free Report) has been gaining investor confidence on consistently positive results. Over the past six months, the stock has gained 21.8% against its industry’s 17.8% decline. Also, the company has outperformed the S&P 500’s 0.7% increase. (4-0)

Here's Why You Should Invest in BioScrip (BIOS) Right Now

2018-07-12 zacks
BioScrip, Inc. (BIOS - Free Report) has been gaining investors’ confidence on consistently positive results. Over the past three months, the company’s stock has outperformed its industry. The stock has gained 23.8%, compared with the industry’s 11%. The company has also outperformed the 5.5% gain of the S&P 500 market as well. (4-0)

Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?

2018-07-12 zacks
Abbott’s (ABT - Free Report) Medical Devices business has been going strong of late on solid sub-segmental performance. (4-0)

Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

2018-07-11 zacks
Achillion Pharmaceuticals, Inc. (ACHN - Free Report) announced that it has initiated a phase I study on its next-generation, oral, alternative pathway factor D inhibitor, ACH-5548. Interim data from the same is expected during the second half of 2018. (6-0)